Suppr超能文献

2型糖尿病:肥胖对于糖尿病性视网膜病变是好还是坏?一项横断面研究。

Type 2 diabetes: is obesity for diabetic retinopathy good or bad? A cross-sectional study.

作者信息

Chen Zheyuan, Zhong Xuejing, Lin Ruiyu, Liu Shuling, Cao Hui, Chen Hangju, Cao Baozhen, Tu Mei, Wei Wen

机构信息

Department of Endocrinology, Fujian Longyan First Hospital, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, 364000, China.

Department of Endocrinology, Fujian Longyan First Hospital, Fujian Medical University, Fuzhou, 350004, China.

出版信息

Nutr Metab (Lond). 2024 Aug 19;21(1):68. doi: 10.1186/s12986-024-00842-8.

Abstract

BACKGROUND

The relationship between obesity and diabetic retinopathy (DR) remains controversial, and the relationship between sarcopenic obesity and DR is still unclear. The purpose of this study is to investigate the relationship between obesity, sarcopenic obesity, and DR in patients with type 2 diabetes mellitus (T2DM).

METHODS

A cross-sectional study was conducted on patients with T2DM. Obesity was assessed by body mass index (BMI), fat mass index (FMI), android fat mass, gynoid fat mass, and visceral adipose tissue (VAT) mass. Sarcopenia was defined according to the criteria of Consensus of the Asian Working Group for Sarcopenia (AWGS 2019). Sarcopenic obesity was defined as the coexistence of sarcopenia and obesity. The association between obesity, sarcopenic obesity, and DR was examined using univariable and multivariable logistic regression models.

RESULTS

A total of 367 patients with T2DM (mean age 58.3 years; 57.6% male) were involved in this study. The prevalence of DR was 28.3%. In total patients, significant adverse relationships between obesity and DR were observed when obesity was assessed by BMI (adjusted odds ratio [aOR] 0.54, 95% confidence interval [CI] 0.31 to 0.96, p = 0.036), FMI (aOR 0.49, 95% CI 0.28 to 0.85, p = 0.012), android fat mass (aOR 0.51, 95% CI 0.29 to 0.89, p = 0.019), gynoid fat mass (aOR 0.52, 95% CI 0.30 to 0.91, p = 0.021) or VAT mass (aOR 0.45, 95% CI 0.25 to 0.78, p = 0.005). In patients with T2DM and obesity, the prevalence of sarcopenic obesity was 14.8% (n = 23) when obesity was assessed by BMI, 30.6% (n = 56) when assessed by FMI, 27.9% (n = 51) when assessed by android fat mass, 28.4% (n = 52) when assessed by gynoid fat mass, and 30.6% (n = 56) when assessed by VAT mass. Sarcopenic obesity was associated with DR when obesity was assessed by BMI (aOR 2.61, 95% CI 1.07 to 6.37, p = 0.035), android fat mass (aOR 3.27, 95% CI 1.37 to 7.80, p = 0.007), or VAT mass (aOR 2.50, 95% CI 1.06 to 5.92, p = 0.037).

CONCLUSIONS

Patients with T2DM showed a substantial inverse relationship between DR and obesity, and sarcopenic obesity was considerably favorably associated with DR. Detection of sarcopenia in patients with T2DM, especially in obese T2DM, is essential to guide clinical intervention in DR.

摘要

背景

肥胖与糖尿病视网膜病变(DR)之间的关系仍存在争议,肌肉减少性肥胖与DR之间的关系也尚不明确。本研究旨在探讨2型糖尿病(T2DM)患者中肥胖、肌肉减少性肥胖与DR之间的关系。

方法

对T2DM患者进行了一项横断面研究。通过体重指数(BMI)、脂肪量指数(FMI)、男性型脂肪量、女性型脂肪量和内脏脂肪组织(VAT)量评估肥胖情况。根据亚洲肌少症工作组共识(AWGS 2019)标准定义肌少症。肌肉减少性肥胖定义为肌少症和肥胖并存。使用单变量和多变量逻辑回归模型检验肥胖、肌肉减少性肥胖与DR之间的关联。

结果

本研究共纳入367例T2DM患者(平均年龄58.3岁;57.6%为男性)。DR的患病率为28.3%。在所有患者中,当通过BMI(调整优势比[aOR] 0.54,95%置信区间[CI] 0.31至0.96,p = 0.036)、FMI(aOR 0.49,95% CI 0.28至0.85,p = 0.012)、男性型脂肪量(aOR 0.51,95% CI 0.29至0.89,p = 0.019)、女性型脂肪量(aOR 0.52,95% CI 0.30至0.91,p = 0.021)或VAT量(aOR 0.45,95% CI 0.25至0.78,p = 0.005)评估肥胖时,观察到肥胖与DR之间存在显著的负相关关系。在T2DM和肥胖患者中,当通过BMI评估肥胖时,肌肉减少性肥胖的患病率为14.8%(n = 23),通过FMI评估时为30.6%(n = 56),通过男性型脂肪量评估时为27.9%(n = 51),通过女性型脂肪量评估时为28.4%(n = 52),通过VAT量评估时为30.6%(n = 56)。当通过BMI(aOR 2.61,95% CI 1.07至6.37,p = 0.035)、男性型脂肪量(aOR 3.27,95% CI 1.37至7.80,p = 0.007)或VAT量(aOR 2.50,95% CI 1.06至5.92,p = 0.037)评估肥胖时,肌肉减少性肥胖与DR相关。

结论

T2DM患者中DR与肥胖之间存在显著的负相关关系,且肌肉减少性肥胖与DR显著正相关。检测T2DM患者尤其是肥胖T2DM患者的肌少症对于指导DR的临床干预至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ead6/11334401/c9f50847f2c1/12986_2024_842_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验